Kyleena

Levonorgestrel, the active ingredient in Kyleena, is a progestin presented as a 19.5 mg intrauterine system for intrauterine use. It provides reversible contraception and can be used to manage heavy menstrual bleeding in women of reproductive age. The device releases levonorgestrel locally over several years, offering high efficacy with minimal systemic exposure.

GNH USA supplies Kyleena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global markets.

Kyleena, a levonorgestrel‑releasing intrauterine system, is indicated for several gynecologic indications.

- Contraception: provides highly effective, reversible birth control for women seeking long‑term prevention of pregnancy. - Heavy menstrual bleeding: reduces menstrual blood loss and improves quality of life in women with menorrhagia. - Post‑partum or post‑abortion contraception: offers continued contraception during the postpartum period.

Like all hormonal contraceptives, Kyleena may be associated with adverse reactions.

Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or abdominal cramping

Serious or Rare Side Effects: - Uterine perforation during insertion - Expulsion of the device - Pelvic inflammatory disease

Before prescribing Kyleena, clinicians should evaluate several safety considerations.

- Pregnancy: contraindicated (Category X); do not insert in pregnant women. - Breastfeeding: assess risk‑benefit; may be used with caution. - History of uterine abnormalities (e.g., fibroids, scarring): evaluate suitability before insertion. - Current pelvic infection: treat and resolve infection prior to device placement. - Smoking: advise cessation, especially in women over 35 years. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel may interact with other medicines that affect hormone metabolism.

Major Interactions (Avoid): - Enzyme inducers (e.g., carbamazepine, phenytoin, rifampin): may reduce levonorgestrel efficacy. - Antiretroviral drugs (e.g., efavirenz): can lower hormone levels. - Certain antibiotics (e.g., rifampin): may compromise contraceptive effect.

Moderate Interactions (Monitor Closely): - St. John’s wort: may modestly decrease hormone concentrations. - Antifungal agents (e.g., ketoconazole): potential to alter metabolism. - Hormonal therapies (e.g., combined oral contraceptives): concurrent use may affect bleeding patterns.